Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?

Journal of hepatology - 1 Oct 2007

Marcellin Patrick, Heathcote E Jenny, Craxì Antonio

Abstract excerpt

The on-treatment virological response to pegylated interferon plus ribavirin therapy is a useful tool in the management of patients with chronic hepatitis C. The time at which hepatitis C virus RNA becomes undetectable by a sensitive PCR assay has a huge impact on the probability of achieving a s...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Administration Schedule
Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Patient Selection

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 17692991
DOI: 10.1016/j.jhep.2007.07.015

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17692991-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?PMID 17692991Read ↗

Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon-alpha 2a plus ribavirin.Semantic proximity Read ↗

Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients.Semantic proximity Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.Semantic proximity Read ↗

Extended-therapy duration for chronic hepatitis C, genotype 1: the long and the short of it.Semantic proximity Read ↗

Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response.Semantic proximity Read ↗

Optimal treatment duration for patients with HCV genotype 1 infection.Semantic proximity Read ↗

"12 weeks' stopping rule" in the treatment of genotype 1 chronic hepatitis C: two prognostic categories under the same label?Semantic proximity Read ↗

Hepatitis C treatment: shorter and better?Semantic proximity Read ↗

Expert opinion on the treatment of patients with chronic hepatitis C.Semantic proximity Read ↗

Hepatitis C treatment response kinetics and impact of baseline predictors.Semantic proximity Read ↗

'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?Semantic proximity Read ↗

Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.